Related Experiment Videos
Clinical developments in reduced intensity haematopoietic stem cell transplantation
William J Hogan1, Rainer Storb
1Programme in Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Expert Opinion on Biological Therapy
|October 22, 2002
Summary
Reduced intensity conditioning regimens for haematopoietic stem cell transplantation (HSCT) offer a less toxic immunotherapy for blood cancers and genetic disorders. These regimens expand HSCT eligibility to older or medically ineligible patients, enabling new therapeutic approaches.
Area of Science:
- Hematology
- Immunology
- Stem Cell Biology
Background:
- Reduced intensity conditioning (RIC) regimens for allogeneic haematopoietic stem cell transplantation (HSCT) have evolved significantly since the 1970s.
- RIC is increasingly vital as an immunotherapy for hematological and select solid organ malignancies.
- It offers an alternative for patients ineligible for conventional HSCT due to age or medical issues.
Purpose of the Study:
- To highlight the advancements and applications of reduced intensity conditioning regimens in HSCT.
- To discuss the potential of RIC in treating inherited gene defects.
- To emphasize the role of stem cell research in developing novel therapies.
Main Methods:
- Review of historical development and current applications of RIC in HSCT.
- Discussion of patient eligibility criteria and expansion through RIC.
- Exploration of stem cell research findings relevant to therapeutic approaches.
Main Results:
- RIC regimens have become a key immunotherapy for various cancers.
- Minimally toxic conditioning enables HSCT for previously ineligible patient groups.
- RIC facilitates the potential treatment of inherited disorders via gene correction through stem cell transplantation.
Conclusions:
- Reduced intensity conditioning regimens represent a significant advancement in HSCT.
- These regimens broaden the therapeutic window for HSCT, making it accessible to more patients.
- Ongoing stem cell research holds promise for innovative treatments for malignant and inherited diseases using HSCT.